this is veronika igorevna pioneer production, then immediately clarifying the question just about vaccines, because you just said, and due to what it is possible to find, uh, some components that used to be imported, and now we are replacing them with domestic developments. and if there is some kind of shortage, we are not somehow engaged in replacing my somehow ahead of the curve. we create our technologies according to our own know-how, but rely, as a basic zero platform, on what is already known in the world . this allowed us, uh, to develop several. analogous platforms first of all, these are recombinant protein vaccines, which include the convassel vaccine against regalia 2, but this is also a new platform, a polysaccharide conjugate vaccine, which can help us now replace expensive american vaccines , moreover, they will be more accurate addresses will work with those serotypes that characterize the russian federation and we have all types of mba vaccines, we are developing inactivated subunit activated and vector vaccines, so the bottom line is that there should be a line of possibil

russian fund accepted investments in order to strengthen the export potential of this pioneer product. veronika igorevnaestion just about vaccines. may be, now they were saying, but due to what it is possible to find, and some components that used to be imported, and now you are replacing them with domestic developments. and is there any kind of shortage, we are not engaged in import substitution , somehow ahead of me. we create our technologies according to our own know-how, but rely, as a basic zero platform, on what is already known in the world . this allowed us, uh, to develop several.